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Abstract
Cancer cells utilize the forces of natural selection to evolve evolvability allowing a 
constant supply of heritable variation that permits a cancer species to evolutionary 
track changing hazards and opportunities. Over time, the dynamic tumor ecosystem 
is exposed to extreme, catastrophic changes in the conditions of the tumor—natural 
(e.g., loss of blood supply) or imposed (therapeutic). While the nature of these catas-
trophes may be varied or unique, their common property may be to doom the current 
cancer phenotype unless it evolves rapidly. Poly-aneuploid cancer cells (PACCs) may 
serve as efficient sources of heritable variation that allows cancer cells to evolve rap-
idly, speciate, evolutionarily track their environment, and most critically for patient 
outcome and survival, permit evolutionary rescue, therapy resistance, and metasta-
sis. As a conditional evolutionary strategy, they permit the cancer cells to accelerate 
evolution under stress and slow down the generation of heritable variation when 
conditions are more favorable or when the cancer cells are closer to an evolutionary 
optimum. We hypothesize that they play a critical and outsized role in lethality by 
their increased capacity for invasion and motility, for enduring novel and stressful 
environments, and for generating heritable variation that can be dispensed to their 
2N+ aneuploid progeny that make up the bulk of cancer cells within a tumor, provid-
ing population rescue in response to therapeutic stress. Targeting PACCs is essential 
to cancer therapy and patient cure—without the eradication of the resilient PACCs, 
cancer will recur in treated patients.
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1  | INTRODUC TION
All cancer would be curable if it were not for metastases and if me-
tastases were not resistant to cancer therapies. These features re-
sult in the death of nearly 10 million people worldwide each year 
and close to 1,600 deaths every day in the USA (Bray et al., 2018; 
Siegel, Miller, & Jemal, 2018). These two properties—metastatic suc-
cess and therapy resistance—occur because cancer cells are under 
selection to evolve traits that generate heritable variation: evolvabil-
ity. That is, evolvability describes the capacity to evolve. Heritable 
variation is the fuel for natural selection. The rate of evolution in 
response to environmental circumstances is the product of heritable 
variation and the force of selection.
Cancer cells utilize the forces of natural selection to evolve evolv-
ability. Evolvability describes a system where variation in phenotype 
is (a) heritable and (b) adaptive. The diverse cancer species inhabiting 
a patient initiate as a single monophyletic clade arising from a com-
mon ancestor in a speciation event where a lineage of normal cells 
goes from being part of the whole organism's fitness function to be-
coming its own self-defined evolutionary fitness function (Table 1). 
Upon becoming the unit of selection, the initiating species of the 
cancer cell clade will be far from any evolutionary optimum. Being 
on the slope rather than the peak of its adaptive landscape means 
that traits conferring greater heritable variation will be favored. In 
addition, the heterogeneity of the emerging tumor can select for a 
diversity of cancer cells. A cancer cell with the capacity to generate 
heritable variation (evolvability) will be able to diversify more rap-
idly into different species that specialize on various aspects of tumor 
heterogeneity. A slower evolving species of cancer cells will be pre-
empted by the faster evolving species. Furthermore, any given re-
gion of a tumor is not static. There are constant changes in immune 
infiltration, blood flow, oxygen, pH, and toxic metabolite buildups 
(Amend & Pienta, 2015). Any evolutionary optimum, therefore, is 
constantly shifting, and the constant supply of heritable variation 
permits a cancer species to evolutionary track changing hazards and 
opportunities. Over time, the dynamic tumor ecosystem may also 
be exposed to extreme, catastrophic changes in the conditions of 
the tumor—natural (e.g., loss of blood supply) or imposed (therapeu-
tic). While the nature of these catastrophes may be varied or unique, 
their common property may be to doom the current cancer pheno-
type unless it evolves rapidly to its dire circumstances. In the ecology 
of threatened species in nature, this is referred to as evolutionary 
rescue (Carlson, Cunningham, & Westley, 2014; Gomulkiewicz & 
Holt, 1995; Hammarlund, Von Stedingk, & Påhlman, 2018). While 
the details of a given catastrophe cannot be anticipated, evolving 
evolvability permits cancer species to adapt to the unexpected—and 
often catastrophic—temporal and special events.
Genetic instability, one of the hallmarks of cancer, enables can-
cer cells to evolve evolvability as an adaptation (Coffey, 1998; Cree 
& Charlton, 2017; Duesberg, Rausch, Rasnick, & Hehlmann, 1998; 
Hanahan & Weinberg, 2011; Heng et al., 2011; Loeb, Bielas, & 
Beckman, 2008; Maley et al., 2006; Mitelman, 2006; Tian, Olson, 
Whitacre, & Harding, 2010). There are several ways by which cancer 
cells can evolve to generate heritable variation that can be subjected 
to natural selection. Gene duplication permits mutation of one copy 
while retaining the original function of the other. Duplications permit 
the upregulation and amplification of useful metabolic processes. 
Conversely, gene deletions or epigenetic silencing by methylation 
can downregulate costly or unnecessary metabolic activities that 
are legacies of the normal cell's whole-organism functions. Lax DNA 
repair mechanisms or other increases in mutation rates can contrib-
ute to greater heritable variation. Chromosomal rearrangements can 
change gene expression and gene regulation in ways that suppress 
or uncover new heritable variants. Increased demethylation of ar-
bitrary or specific histones provides ways of creating heritable epi-
genetic variation that can cause single genes or suites of genes to be 
unmasked and expressed. Examples from other species suggest that 
chromosomal rearrangements that may significantly amplify herita-
ble genetic variation could be more common in polyploid cancer cells 
(James, Usher, Campbell, & Bond, 2008; Selmecki et al., 2015; Yao, 
Carretero-Paulet, & Van de Peer, 2019). The repeatable evolution of 
poly-aneuploid forms of cancer species may be the primary culprit 
and the prime adaptation for cancers’ evolvability.
2  | POLY-ANEUPLOID C ANCER CELL S A S A 
CONSTR AINT-BRE AKING ADAPTATION FOR 
STRESS RESISTANCE AND E VOLVABILIT Y
Multiple studies have described a minority population of physi-
cally large cancer cells within the tumors of patients with meta-
static disease. This likely holds for most, if not all, cancer types that 
have the potential to result in therapeutically resistant metastases. 
These large cancer cells have unusually high genomic content (i.e., 
poly-aneuploid) and exhibit remarkable resilience to stress (Amend 
et al., 2019; Brooks, Glogauer, & McCulloch, 2019; Chen et al., 2019; 
Erenpreisa & Cragg, 2013; Fei et al., 2015; Illidge, Cragg, Fringes, 
Olive, & Erenpreisa, 2000; Mirzayans, Andrais, & Murray, 2018; Niu, 
Mercado-Uribe, & Liu, 2017; Zhang et al., 2014).
Virtually, all cancer cells are aneuploid (i.e., 2N+), containing an 
abnormal number of chromosomes or chromosomal fragments. The 
2N+ cells display structural rearrangements, amplifications, and 
deletions. Polyploid describes increased DNA content of the cell's 
genome in its entirety. While polyploidy indicates complete sets of 
chromosomes, aneuploidy indicates varied copy numbers that may 
be specific for different chromosomes or chromosomal fragments 
within a single cell (Ben-David & Amon, 2019). Thus, poly-aneu-
ploidy describes a whole-genome increase in an aneuploid genome. 
Cancer cells with relative high genomic content generally occur at 
low frequencies and as poly-aneuploids exist as 4N+, 6N+, or greater 
(Table 2).
It seems that cancer species are able to exist in both 2N+ and 
poly-aneuploid states, and that cancer cells of a clade shift between 
these states. As the poly-aneuploids revert back to a 2N+ state, 
those that retain odd numbers of chromosomes or chromosome 
fragments might be more fit than those that do not. Thus, by the 
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time the cancer is clinically detectable perhaps all of the observable 
cancer cells have cycled one or more times between poly-aneuploid 
and 2N+ states.
We suggest that these poly-aneuploid cancer cells (PACCs) (also 
referred to in the literature as polyploid giant cancer cells (PGCCs), 
multinucleated giant cancer cells, blastomere-like cancer cells, os-
teoclast-like cancer cells, and pleomorphic cancer cells) are a key 
adaptation that is repeated across virtually all patients with lethal 
cancer (Amend et al., 2019; Brooks et al., 2019; Chen et al., 2019; 
Fei et al., 2015; Illidge et al., 2000; Jinsong, 2019; Mirzayans et al., 
2018; Mittal et al., 2017; Niculescu in-press; Niu et al., 2017; Ogden, 
Rida, Knudsen, Kucuk, & Aneja, 2015; Zhang et al., 2014). We have 
adopted the naming convention of “poly-aneuploid cancer cell” to 
emphasize (a) the distinction from normally polyploid cells/states 
(e.g., osteoclasts, blastomeres) derived from diploid progenitors, (b) 
the inclusion of both multinucleated and mononucleated PACCs, and 
(c) the aneuploid genome baseline of the polyploid genome.
We hypothesize that PACCs play a critical and outsized role in 
lethality by (a) their increased capacity for invasion and motility (high 
metastatic potential); (b) for enduring novel and stressful environ-
ments (successfully metastasize and be intrinsically therapy-resis-
tant); and (c) for generating heritable variation that can be dispensed 
to their 2N+ aneuploid progeny that make up the bulk of cancer cells 
within a tumor (providing population rescue) (Amend et al., 2019; 
Carlson et al., 2014; Lin et al., 2019).
Poly-aneuploid cancer cells have been documented as emerging 
in response to stress, including therapeutic stress such as chemo-
therapy (Figure 1) (Amend et al., 2019; Lin et al., 2019, 2017). These 
data include tightly controlled in vitro assays as well as clinical data 
demonstrating increased PACC numbers in ovarian cancer patients 
following chemotherapy (Niu et al., 2017). Compellingly, published 
data also show that pressures present in the tumor microenviron-
ment, such as low oxygen, induce the emergence of PACCs in vitro. 
PACCs are more common in metastatic lesions than in primary tu-
mors, and they are more common in the primary tumors of patients 
with metastasis than those who have strictly localized disease (Fei 
et al., 2015). The presence of PACCs in the diagnostic specimen 
of prostate cancer predicts a dismal prognosis, with rapid disease 
Term Definition
Species A group of similar and related individuals defined by 
genetic separation and phenotypic differentiation 
from other species
Clade A group of species that all evolved from a single 
ancestor
Evolvability A biological system in which phenotypic variation 
is both heritable and adaptive; capable of adaptive 
evolution
TA B L E  1   Evolutionary terms and 
definitions
Diploid Two complete sets of chromosomes; normal in a mammalian cell (2N)
Aneuploid An abnormal number of chromosomes or chromosome fragments, including 
structural rearrangements, amplifications, and deletions (2N+)




One or more complete whole-number duplications of an aneuploid genome 
(>4N+)
TA B L E  2   Genomic content terms and 
definitions
F I G U R E  1   (a and b) Prostate cancer cell line PC3 treated with docetaxel for 6 days shows nearly all surviving cells are PACCs. (a) PACCs 
indicated by white arrow; non-PACC indicated by black arrow; (b) shows an identical image with PACCs outlined for clarity (scale = 200 µM). 
(c) Invasive high grade papillary urothelial carcinoma H&E shows region of focal PACCs (indicated by white arrow)
(a) (b) (c)
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progression and reduced overall survival (Alharbi, Marzo, Hicks, 
Lotan, & Epstein, 2018). Different functional events can produce 
PACCs including cell–cell fusion, endoreplication, and acytokinesis. 
It remains unclear whether one of these mechanisms predominates 
or whether they have different biological consequences (Amend 
et al., 2019; Chen et al., 2019; Illidge et al., 2000; Jinsong, 2019; Lin 
et al., 2019, 2017; Mirzayans et al., 2018).
Data suggest that PACCs survive dynamic environments (e.g., 
sudden onset of hypoxia or nutrient poverty) by exiting the cell cycle 
and entering quiescence or reversible therapy-induced senescence, 
therefore protecting their genome and avoiding programmed cell 
death (Lopez-Sanchez et al., 2014). The formation of a PACC phe-
notype is also associated with an increased capacity for motility and 
invasion. Motility allows PACCs to physically move into new envi-
ronments, a rare feature among largely sessile epithelial cells (Fei 
et al., 2015). The quiescent state primes PACCs to survive the stress 
of circulation and colonization of a new metastatic site. Likewise, 
the quiescent PACCs survive anticancer therapy by protecting their 
DNA from damage and the subsequent activation of apoptotic pro-
grams. Once therapeutic stress is removed, as is the case with in-
termittent chemotherapy or tumor microenvironment hypoxia, the 
PACCs reenter the cell cycle and utilize their high genomic content 
to repopulate the tumor with nonpolyploid progeny. Reversion hap-
pens through a variety of potential mechanisms, including neosis 
(cell budding) and successful multipolar cell division (Amend et al., 
2019; Chen et al., 2019; Illidge et al., 2000; Jinsong, 2019; Lin et al., 
2019, 2017; Mirzayans et al., 2018). The progeny represents diverse 
heritable variants that propels further evolution of ecological niche 
filling and resistance.
Species of cancers within the tumor that can produce PACCs 
as a contingent strategy likely out-survive those that do not. The 
capacity to form PACCs and then to return to non-poly-aneuploid 
states may be regarded as a key event occurring early in the can-
cer's phylogeny. Cancer cell species that can form PACCs replace 
those that cannot. Frequent occurrence of stochastic environmental 
stresses within a cancer population's microenvironment may provide 
the initial selection for creating PACC morphs. The PACC morph cre-
ates a resilient phenotype with several properties that are advanta-
geous for responding to future stresses that any successful cancer 
species likely encounters over time. By providing a morph that pro-
vides robust resilience, PACCs predispose the cancer cell lineage 
for surviving and evolving to the unexpected. For example, being 
a circulating tumor cell that finds itself in a distant tissue and being 
exposed to anticancer therapy represent two unexpected and highly 
negative stressors for which PACCs may be cancer's solution. PACCs 
can provide the source of the “rescue effect” associated with the 
catastrophic event of therapeutic intervention (Carlson et al., 2014). 
The formation of PACCs, then, may represent the common conver-
gent evolutionary event across patients that actuates metastasis and 
therapeutic resistance.
Poly-aneuploid cancer cells provide a notable advantage over 
other mechanisms for generating heritable variation or evolvability 
(Amend et al., 2019; Brooks et al., 2019; Chen et al., 2019; Mirzayans 
et al., 2018, Vincent, Cohen, & Brown, 1993): PACC formation can 
be facultative. This means it can be modulated up and down as a 
contingent strategy. Increased mutation rates or reduced gene re-
pair mechanisms can provide a steady supply of heritable variation. 
There may be contingencies when generating heritable variation at 
a high rate is disadvantageous (when traits are near evolutionary 
optima or when most genetic or epigenetic mutations are nonben-
eficial) and when it is advantageous for other contingencies (evolu-
tionary rescue or evolutionary tracking). As a conditional strategy, 
PACCs permit the cancer cells to accelerate evolution under stress 
and slow down the generation of heritable variation when condi-
tions are more favorable or when the cancer cells are closer to an 
evolutionary optimum. That is, PACCs allow for facultative evolv-
ability. In vitro experiments found that PACCs exist at a very low 
frequency within a cancer cell's population when the population 
experiences a consistent culturing regimen. Upon application of a 
lethal drug, PACCs increased in frequency to become the majority of 
cells (Lin et al., 2019). The higher mortality of 2N+ morphs partially 
explains some of the increase, but some of the increase comes from 
the rapid transformation of 2N+ cells into PACCs. With continued 
application of the drug, the PACCs produced the heritable variation 
needed for the emergence of fully resistant 2N+ cells (Amend et al., 
2019; Lin et al., 2017). The now resistant population saw the prolif-
eration of 2N+ morphs to repopulate the cancer species that then 
resumed a very low rate of transformation in PACCs. PACCs once 
again occurred at only low frequencies. Presumably over the evo-
lutionary course of a cancer cell lineage, cells that produce PACCs 
facultatively have an advantage over those that have fixed rates of 
transforming cells into and out of PACCs.
3  | PREPAREDNESS FOR THE 
UNE XPEC TED IS CRITIC AL TO THE 
E VOLUTION OF E VOLVABILIT Y
Inherited traits acquired through natural selection can be utilized 
for unexpected needs. For example, an organisms’ ability to hold 
its breath to prevent noxious toxins entering the lungs enables the 
otherwise unrelated trait of swimming underwater. The ability to 
form and then resolve PACCs may be a repeatable—and perhaps 
the most successful—adaptation for responding to strongly negative 
rare events that would otherwise be catastrophic for the cancer cell 
population. PACCs may allow the cancer cell species to win twice. 
First, by utilizing quiescence, PACCs are inherently more resistant 
to stressors than neighboring cycling 2N+ cells. Second, by utilizing 
their extra genomic content, PACCs accelerate the evolution of di-
verse solutions to these novel stressors. To our knowledge, no other 
form of genetic instability can provide both.
Cancer cell species that can produce PACCs, therefore, may rep-
resent an evolutionary archetype—an entity that has evolved the 
capacity for evolvability through increased, protected, and mobile 
genomic content. A central dogma of genetics reflects that the archi-
tecture of a genetic system simultaneously permits and constrains 
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the heritable variation available to natural selection. A normal dip-
loid cell, for example, is genetically and epigenetically programmed 
to perform a tissue-specific set of tasks. A liver cell and a kidney 
cell each have the same genetic material but perform vastly differ-
ent functions that are tightly regulated. Due to their increased and 
disordered genetic content, PACCs circumvent this architecture. 
PACCs evolve swiftly by providing heritable variation at a rate not 
available within a normal diploid cell (Yang et al., 2019). Similarly, uti-
lizing aneuploidy to enable cross-adaptation to therapeutic agents 
has been demonstrated in yeast, allowing rapid development of re-
sistance in response to stress (Selmecki et al., 2015; Storchova et al., 
2006). Natural selection can only respond to what has happened or 
is happening.
The certainty that a cancer cell will encounter rare circumstances 
is why natural selection can evolve evolvability as an adaption. Upon 
initiation, cancer cells are likely far from any evolutionary optimum. 
Natural selection will favor cells that evolve the most swiftly up their 
adaptive landscapes, toward the point where a cancer cell cannot 
improve one attribute without sacrificing another (defined as Pareto 
efficiency) (Henry, Hemery, & Francois, 2018; de Jong, 2007; Lloyd 
et al., 2016; Ng, Wang, Chowdhury, & Maranas, 2019; Schuech, 
Hoehfurtner, Smith, & Humphries, 2019). If uncertain catastrophic 
perturbations occur in a cancer cell's environment (or if the cancer 
cell unexpectedly finds itself in a completely foreign environment, 
e.g., metastasis), then it must evolve evolvability in response to the 
near certainty of catastrophic perturbations even if the exact na-
ture or timing of a future perturbation is uncertain and unknown. 
Ironically, natural selection imbues most organisms with adaptations 
for dealing with the expectedness of the unexpected. This evolution 
of evolvability through PACCs has profound implications for under-
standing tumorigenesis and therapeutic resistance.
4  | CONVERGENT E VOLUTION OF PACC S
The PACC phenotype represents a convergent adaptive response 
to stress. It appears to happen in all cancer cell lineages across all 
patients with metastatic disease. PACCs likely allow the cancer cells 
to produce gene duplications, repurpose redundant genes, gener-
ate novel variants from chromosomal rearrangements, and, perhaps 
most significantly, epigenetically access cellular programs typically 
restricted to subsets of tissue cell types, for example, macrophages, 
osteoclasts, and trophoblasts (Brooks et al., 2019; Diaz, Wood, 
Sibley, & Greenwood, 2014; Pereira et al., 2018; Yang et al., 2019). 
For example, PACCs may allow the cancer cells to utilize different 
metabolic strategies, movement characteristics, and stress response 
that is typical of these normal somatic polyploid cells. Such large 
multinucleated cells in normal tissues, found in humans as well as 
model animal systems (murine, D. melanogaster, and C. elegans), are 
nonproliferative and highly motile following the cell biology dogma 
of “differentiate versus proliferate”(Amini et al., 2015; Brooks et al., 
2019; Diaz et al., 2014; Kim, Jin, Duan, & Chen, 2015; Pereira et al., 
2018; Simionescu & Pavlath, 2011). These normal somatic polyploid 
cells, however, do not return to a 2N state, thus restricting their 
evolvability, a necessary constraint for maintaining total-organism 
integrity and reducing malignant transformation of these cells.
Notably, PACC characteristics are not restricted to eukaryotic 
cells, are also observed in other organisms, and emerge as an adap-
tation to stress, providing evidence for ancestral genetic programs. 
Yeast, as noted above, exhibit a near equivalence of PACCs (Selmecki 
et al., 2015; Storchova et al., 2006). Some yeast form polyploids 
through meiosis without cytokinesis in response to toxins or adverse 
physical conditions. This permits rapid evolution of appropriate 
stress responses and later a return to a euploid state (Selmecki et al., 
2015; Storchova et al., 2006; Yang et al., 2019). Tetrahymena vorax, a 
protist species of ciliate, exhibits two exemplars of stress-contingent 
strategies (Gronlien, Hagen, & Sand, 2011). When food is generally 
unavailable, they can duplicate their genome to be essentially poly-
ploid. When favorable times return, they reenter the cell cycle and 
can sustain several rounds of cell division without having to enter 
interphase and duplicate their DNA. It is unknown whether diverse 
heritable variants become possible as a result of this polyploid 
state. A number of protist species that exist in a haploid state will 
cease asexual reproduction and engage in sex by fusing into a 2N 
“polyploid” morph that subsequently undergoes meiosis to produce 
four 1N offspring. Similarly, some of invertebrate metazoans typi-
cally reproduce asexually and only engage in sex (via a “polyploid” 
state) when the environmental conditions become poor (e.g., water 
fleas, Daphnia) (Adamowicz, Gregory, Marinone, & Hebert, 2002; 
Vergilino, Markova, Ventura, Manca, & Dufresne, 2011; Xu et al., 
2015). The ancient ameboid protist class Foraminifera alternates be-
tween haploid and polyploid states as a means of reproduction, even 
when conditions are completely devoid of oxygen (Akimoto, Hattori, 
Uematsu, & Kato, 2001; Pawlowski et al., 2003; Risgaard-Petersen 
et al., 2006). The resulting propagules can be quiescent for years 
before starting to grow (Alve & Goldstein, 2010). Through passive 
suspension transport, these propagules have a remarkable ability to 
quickly colonize new habitats through opportunistic and pioneer-
ing species (Alve & Goldstein, 2003). Overall, versatile solutions to 
fluctuating ecological conditions are associated with the capacity for 
alternating genomic contents, resistance, and motility. PACCs seem 
to be recapitulating this adaptation that has been successful in so 
many free-living unicellular species that have colonized virtually all 
places on Earth.
5  | TARGETING THE E VOLVABLE 
E VOLVABILIT Y OF PACC S WILL BE 
NECESSARY TO CURE LETHAL C ANCER
We see targeting PACCs as essential to cancer therapy and patient 
cure. Without the eradication of the resilient PACCs, cancer will 
recur in treated patients. One strategy to target these critical cells is 
to turn their capacity for evolvability into a fatal handicap. An evo-
lutionary trap describes a situation in which an organism adopts an 
adaptive trait in response to an evolutionary environmental pressure 
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that inadvertently makes it vulnerable to another environmental 
stressor (Basanta, Gatenby, & Anderson, 2012; Gatenby & Brown, 
2018; Robertson, Rehage, & Sih, 2013). In essence, the organism is 
“tricked” into adopting a trait that will soon become extremely mala-
daptive. Known in evolutionary game theory as an evolutionary dou-
ble-bind, this strategy can be exploited to treat cancer cells that are 
otherwise resistant to conventional therapy combinations (Basanta 
et al., 2012; Gatenby, Zhang, & Brown, 2019; Zhang, Cunningham, 
Brown, & Gatenby, 2017). Effecting an evolutionary trap requires a 
two-phased approach, with selection of the first agent or condition 
to promote a particular targetable adaptive response followed by an 
agent specifically selected to target the adaptive phenotype (Zhang 
et al., 2017).
The PACC cancer cell phenotype is defined by polyploidy, ac-
companied by an aberrant number of centrosomes (Amend et al., 
2019; Chen et al., 2019; Illidge et al., 2000; Mirzayans et al., 2018). 
To divide evenly, normal cells possess two centrosomes, critical 
components of the microtubule organizing center (MTOC) that de-
fine the two poles of a dividing cell. Studies have shown that suc-
cessful cell division of polyploid cells requires centrosome clustering 
to align mitotic poles and avoid multipolar division, mitotic catastro-
phe, and cell death (Antao, Marcet-Ortega, Cifani, Kentsis, & Foley, 
2019; Navarro-Serer, Childers, Hermance, Mercadante, & Manning, 
2019; Schatten & Ripple, 2018). Kinesin 14 (KIFC1) is essential to 
enable correct centrosome clustering and subsequent asymmetric 
cell division. Importantly, KIFC1 is dispensable in normal cells that 
do not require centrosome clustering, making it an ideal therapeu-
tic target (Li et al., 2015; Sekino et al., 2019; Xiao et al., 2017). It 
may be possible to specifically target this process—only utilized in 
polyploid cells that undergo cell division—to specifically kill PACCs 
(Figure 2). To set the evolutionary trap, chemotherapy would be 
administered to expose the adaptive “evolvable evolvability” PACC 
morph (Basanta et al., 2012; Gatenby & Brown, 2018; Gatenby et al., 
2019; Robertson, Ostfeld, & Keesing, 2017; Robertson et al., 2013; 
Zhang et al., 2017). The emerging PACCs would then be specifically 
targeted with a KIFC1 inhibitor to block centrosome clustering and 
lead to mitotic catastrophe when the cells attempt to divide.
6  | SUMMARY
Poly-aneuploid cancer cells species are isolated across time and 
space (i.e., different metastatic sites within the same patient), but 
utilize similar machinery to survive environmental and therapeutic 
stresses. Observations in cell culture as well as histologic tissues 
demonstrate a variety of PACCs with different genotypes and phe-
notypes within and among each community of cancer cells (Amend 
et al., 2019; Chen et al., 2019; Illidge et al., 2000; Lin et al., 2019, 
2017; Mirzayans et al., 2018). Given that PACCs seem to exist across 
virtually all patients with lethal cancers, the mechanisms that un-
derlie what appears to be a convergent survival mechanism across 
all cancer species must be defined. Just as there are many species 
of cancer cells, there are likely to be many species of cancer cells 
with the capacity to generate PACCs as a conditional state. These 
different species of PACCs, however, must share common genetic or 
epigenetic elements that allow the formation of the poly-aneuploid 
evolvable “genotype/ phenotype” as a shared evolutionary adaptive 
response to stress. Ultimately, PACCs may explain the development 
of cancer lethality across individual patients. The versatility and role 
of PACCs in metastases and therapy resistance provide promising 
insights into possible new approaches to cancer therapy. Indeed, 
PACCs demonstrate characteristics such as genetic and geographic 
versatility that are key within the evolution of ecosystems in nature. 
Probing the characteristics of the PACCs as ecological strengths may 
provide novel ways to disrupt them and their role in rendering the 
metastatic disease lethal and ultimately untreatable.
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